GNLX
Genelux Corporation
NASDAQ · Healthcare · Biotechnology · US
$2.44
−3.17%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -15.3%
- EBIT
- -10.3%
- EPS
- -2.3%
- Free cash flow
- -25.7%
- Operating cash flow
- -12.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +7.3%
- EPS
- +14.9%
Three-year CAGR
- Revenue
- -91.0%
- EBITDA
- -9.0%
- EBIT
- -4.8%
- Net income
- -7.6%
- EPS
- +9.5%
- Free cash flow
- -22.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026